Hostname: page-component-5c6d5d7d68-ckgrl Total loading time: 0 Render date: 2024-08-21T06:58:22.934Z Has data issue: false hasContentIssue false
  • English
  • Français

Infections in Hematologic Malignancy

Published online by Cambridge University Press:  02 January 2015

Tom R. Rogers
Tom R. Rogers*
Affiliation:
Westminster Hospital, Charing Cross and Westminster Medical School, London, England
*
Westminster Hospital, Charing Cross and Westminster Medical School, 17 Horseferry Road, London, England SW1P 2AP
Get access Rights & Permissions [Opens in a new window]

Extract

Two decades have elapsed since the first detailed studies were undertaken to determine which factors were associated with an increased incidence of life-threatening sepsis during the treatment of leukemia and lymphoma. The state of granulocytopenia is now acknowledged to be the major factor predisposing to infection and accordingly, attention has focused on the merits of preventive measures applied during this risk period. A tremendous effort has been invested in the evaluation of different protocols and there is little doubt that major advances have been made even though a simultaneous improvement in survival rates as a result of more intensive chemotherapy has not always been in evidence. While it is appropriate to initiate prophylaxis before the treatment of most adult acute leukemias and for marrow transplantation, the reduced duration and severity of granulocytopenia during chemotherapy for both childhood acute leukemia and lymphoma generally obviate the need for this approach.

Progress in the development of potent broad-spectrum antibiotics coupled with better clinical awareness of the value of early treatment, as well as changing practices in supportive care have each contributed to the recent pattern of infection that has been observed. In addition, the impact of new technologies, as illustrated by recent innovative applications of bone marrow transplantation, further underlines the need to reappraise current infection control procedures.

Type
Research Article
Information
Infection Control & Hospital Epidemiology , Volume 7 , supplement S2: Proceedings of the Second ICI/Stuart Workshop , February 1986 , pp. 140 - 143
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1986

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Bodey, CP, Buckley, M, Sathe, YS, el al: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328–340.Google Scholar
2.Young, LS: Infections in leukemia and lymphoma, in Rubin, RH, Young, LS (eds): Clinical Approach to Infection in ihe Compromised Host. New York, Plenum, 1981, pp 461–506.Google Scholar
3.Pizzo, PA, Rohichaud, KJ, Gill, FA, et al: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72:101–111.Google Scholar
4.Hann, IM, Prentice, HG: Infection prophylaxis in the patitent with bone marrow failure, in Prentice, HG (ed): Clinics in Haematology. London, WB Saunders, Vol 13, No 3, 1984, pp 523–547.Google Scholar
5.EORTC International Antimicrobial Therapy Group: Trimethoprim-Sulfamethoxazole in the prevention of infection in neutropenic patients. J Infect Dis 1984; 150:372–379.Google Scholar
6.Schimpff, SC: Infection prevention during profound granulocytopenia. Ann Intern Med 1980; 93:358–361.Google Scholar
7.Bodey, GP: Current status of prophylaxis of infection with protected environments. Am J Med 1984: 76:678–684.Google Scholar
8.Selwyn, S, Anderson, IS, Rogers, TR: Quantitative studies on the decontamination of skin and mucous membranes in relation to immuno deficient patients, in Fliedner, et al (eds): Clinical and Experimental Gnolobiotics Lembi Bakt Para-silkde Stuttgart Fischer Suppl 7. 1979. pp 281–284.Google Scholar
9.Rogers, TR, Hall, G, Anderson, IS, et al: Factors influencing microbial attachment to buccal epithelial cells in immuno deficient patients, in Sasaki, S (ed): Recent Advances in Germ Free Research. Tokai University Press, 1981, pp 173–177.Google Scholar
10.Levine, AS, Siegel, SE, Schreiber, AD, et al: Protected environments and prophylactic antibiotics. N Engl J Med 1973; 288:477–483.Google Scholar
11.Armstrong, D: Protected environments are discomforting and expensive and do not offer meaningful protection. Am J Med 1984; 76:685–689.Google Scholar
12.Rogers, TR: Prevention of infection in neutropenic bone marrow transplant patients, in Schonfeldh, , Hahn, FE (eds): Antibiotics and Chemotherapy Vol 33 1985, pp 90–113.Google Scholar
13.Cohen, ML, Murphy, MTCounts, GW, et al: Prediction by surveillance cultures of bacteremia among neutropenic patients treated in a protective environment. J Infect Dis 1983; 147:789–793.Google Scholar
14.Darbyshire, PJ, Weightman, NC, Speller, DCE: Problems associated with indwelling central venous catheters. Arch Dis Child 1985; 60:129–134.Google Scholar